High-dose interleukin-2 offers complete response to patients with metastatic renal cell carcinoma
There are independent patient responses to high-dose interleukin-2 and to targeted agents before and after receiving high-dose interleukin-2, according to a recent study. This suggests that carefully selected patients must be given high-dose interleukin-2 for the possibility of a complete and durable response without the fear of limiting the treatment benefit of targeted agents.
Researchers retrospectively reviewed the records of patients with metastatic renal cell carcinoma treated with high-dose interleukin-2 between July 2007 and September 2014 to assess survival outcomes. Clinicopathological data were abstracted and patient response to therapy was based on Response Evaluation Criteria In Solid Tumors (RECIST), version 1.1 criteria.
The authors used the Kaplan-Meier method to estimate progression-free and overall survival in the entire cohort, the response to high-dose interleukin-2 with regard to previous targeted agent therapy, and the response to the targeted agent in relation to the response to high-dose interleukin-2.
Of the 92 patients included in the study, 87 had documentation of a response to high-dose interleukin-2. Median overall survival from the initiation of high-dose interleukin-2 therapy in the entire cohort was 34.4 months.
Overall survival (median 34.4 and 30.0 months; p=0.88) and progression-free survival (median 1.5 and 1.7 months; p=0.8) were similar between patients who received targeted therapy before high-dose interleukin-2 and those who received no prior therapy, respectively.
In addition, patients with a complete or partial response to high-dose interleukin-2 had similar outcomes for subsequent targeted agents vs patients whose best response was stable or progressive disease (median overall survival, 30.1 vs 25.4 months; p=0.4).